Abstract
Ageing is a heterogeneous multisystem process involving different rates of decline in physiological integrity across biological systems. The current study dissects the unique and common variance across body and brain health indicators and parses inter-individual heterogeneity in the multisystem ageing process. Using machine-learning regression models on the UK Biobank dataset (N = 32,593, age range 44.6-82.3, mean age 64.1 years), we first estimated tissue-specific brain age for white and gray matter based on diffusion and T1-weighted magnetic resonance imaging (MRI) data, respectively. Next, bodily health traits including cardiometabolic, anthropometric, and body composition measures of adipose and muscle tissue from bioimpedance and body MRI were combined to predict ‘body age’. The results showed that the body age model demonstrated comparable age prediction accuracy to models trained solely on brain MRI data. The correlation between body age and brain age predictions was 0.62 for the T1 and 0.64 for the diffusion-based model, indicating a degree of unique variance in brain and bodily ageing processes. Bayesian multilevel modelling carried out to quantify the associations between health traits and predicted age discrepancies showed that higher systolic blood pressure and higher muscle-fat infiltration were related to older-appearing body age compared to brain age. Conversely, higher hand-grip strength and muscle volume were related to a younger-appearing body age. Our findings corroborate the common notion of a close connection between somatic and brain health. However, they also suggest that health traits may differentially influence age predictions beyond what is captured by the brain imaging data, potentially contributing to heterogeneous ageing rates across biological systems and individuals.
Competing Interest Statement
OAA is a consultant to cortechs.ai and received speakers honorarium from Lundbeck, Janssen and Sunovion unrelated to the topic of the current study. JL is an employee and shareholder of AMRA Medical AB and reports consulting and speaking honoraria from Eli Lilly and BioMarin unrelated to the topic of the current study. ODL is an employee and shareholder of AMRA Medical AB and reports consulting from Eli Lilly and Fulcrum Therapeutics unrelated to the topic of the current study.
Funding Statement
The Research Council of Norway (#223273, #324252, #300767, #324499), South-Eastern Norway Regional Health Authority (#2017112, #2019101, #2022080, #2020060), European Unions Horizon 2020 Research and Innovation Programme (CoMorMent project, Grant #847776, BRAINMINT project, Grant #802998), the German Federal Ministry of Education and Research (01ZX1904A), and the Swiss National Science Foundation (#PZ00P3_193658, #TMPFP3_217174). We performed this work on the Services for sensitive data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2 (the National Infrastructure for High-Performance Computing and Data Storage in Norway). We conducted this research using the UK Biobank Resource under Application Number 27412.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank resource is open for eligible researchers upon application (http://www.ukbiobank.ac.uk/register-apply/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Addition of funding information and changes following peer-review including addition of supplementary figures and sensitivity analyses.
5. Data availability
The UK Biobank resource is open for eligible researchers upon application (http://www.ukbiobank.ac.uk/register-apply/).
